PRAME T-cell therapy

PRAME (Preferentially Expressed Antigen in Melanoma) targeting therapies encompass two primary modalities: engineered T-cell receptor (TCR) T-cell therapies and recombinant protein vaccines. The TCR-T approach, developed using Adaptimmune's SPEAR (Specific Peptide Enhanced Affinity Receptor) platform, involves engineering a patient's T-cells to express high-affinity receptors specific to PRAME peptides presented by HLA molecules, enabling the targeted destruction of PRAME-positive tumor cells. This program was a key component of a strategic collaboration between Adaptimmune and GSK, which was terminated in late 2022, with rights reverting to Adaptimmune in 2023. Separately, GSK developed a PRAME immunotherapeutic consisting of a recombinant PRAME protein combined with the AS15 immunostimulant. This vaccine was evaluated in Phase I trials for surgically resected non-small cell lung cancer (NSCLC) to induce humoral and cellular immune responses, though further development was halted following disappointing results with similar immunotherapeutics in the same indication.

Other names

PRAME SPEAR T-cell therapyPRAME immunotherapeuticPRAME cancer immunotherapeuticPRAME-targeting therapy